Developer docs
API playgroundTry for free, no card

Search company profiles

Sutro Biopharma

Full company profile

uuid0000tak

Namestring
Sutro Biopharma
Legal namestring
Sutro Biopharma, Inc.
Websiteurl
sutrobio.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, that develops next-generation protein therapeutics for cancer using its proprietary cell-free protein synthesis platform, XpressCF. The platform separates cell-mass production from protein production, enabling rapid parallel evaluation of thousands of protein variants in under 24 hours, efficient site-specific incorporation of non-natural amino acids, and generation of homogeneous single-species antibody-drug conjugates (ADCs) rather than heterogeneous mixtures. Sutro's wholly-owned pipeline comprises tissue factor-targeting exatecan ADC STRO-004 (Phase 1, dosed December 2025), PTK7-targeting STRO-006 (IND planned 2026), and STRO-227 (IND planned late 2026). The company is also advancing immunostimulatory dual-payload ADCs (iADCs) in collaboration with Astellas, with ASP2998 (TROP2-targeted iADC) entering clinical trials in Q2 2026.

Sutro monetizes primarily through strategic collaborations and licensing rather than direct commercialization. Core partnerships include Merck (cytokine derivatives, up to $1.6 billion in potential milestones), Celgene/BMS (BCMA ADC and bispecifics), EMD Serono (up to six ADC targets), Astellas (dual-payload iADCs), and Vaxcyte (exclusive license of XpressCF for pneumococcal conjugate vaccines VAX-31 and VAX-24). A June 2023 royalty financing with Blackstone Life Sciences provided $140 million upfront (with up to $250 million in milestones) in exchange for a 4% royalty interest in Vaxcyte's future product sales. FY2025 collaboration revenue of $102.5 million (65% growth from $62.0 million in 2024) was driven by Astellas and Ipsen milestones, with cumulative collaboration payments reaching approximately $1.016 billion through December 2025.

Following a March 2025 strategic review, Sutro deprioritized luveltamab tazevibulin (STRO-002), reduced its workforce by approximately one third in October 2025, and narrowed focus to three ADC programs. The company operates cGMP manufacturing at a San Carlos facility and benefits from a January 2025 scale-up of XpressCF to 4,500L GMP at Boehringer Ingelheim's Vienna site — the first large-scale third-party CDMO validation of cell-free protein synthesis. As of early 2026, Sutro had a market capitalization of approximately $406 million, ~97% institutional ownership, and a cash position of $141.4 million extended to Q2 2028 following a February 2026 $110 million public offering.

Short descriptiontext

Sutro Biopharma is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for oncology using its proprietary XpressCF cell-free protein synthesis platform, monetizing through pharma collaborations while advancing a focused internal ADC pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-free protein synthesis, antibody-drug conjugates, oncology therapeutics development, biologics manufacturing platform, clinical-stage biopharmaceuticals
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Collaboration and Partnership Revenue
TypeLicensing Royalties
Description

Revenue from upfront payments, research and development funding, milestone payments, and royalty payments from strategic partnerships with pharmaceutical companies including Merck, Celgene, EMD Serono, and Astellas. FY2025 revenue was $102.5 million, a 65% increase from $62.0 million in 2024, driven by collaboration milestones from Astellas and Ipsen.

biospace.com
2Royalty Income from Vaxcyte
TypeLicensing Royalties
Description

Blackstone provides $140 million upfront to Sutro in exchange for 4% royalty interest on future sales of Vaxcyte's products, including pneumococcal conjugate vaccine VAX-24. Sutro retains equity interest in Vaxcyte.

stocktitan.net
3Equity Financing
TypeOne Time License
Description

Underwritten public offerings of common stock to institutional investors. February 2026 offering raised approximately $110 million through sale of 7,868,383 shares at $13.98 per share.

markets.businessinsider.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sutro Biopharma develops next-generation protein therapeutics for cancer using its proprietary XpressCF and XpressCF+ cell-free protein synthesis platforms. The company creates antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine-based therapeutics through site-specific incorporation of non-natural amino acids, producing homogeneous single-species conjugates. Its clinical pipeline includes STRO-004 (tissue factor ADC in Phase 1), STRO-006, and STRO-227, alongside partnered programs with Astellas (ASP2998 iADC) and Vaxcyte (pneumococcal conjugate vaccines).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 65% revenue growth in FY2025 to $102.5 million
+1 more record
Product overview1 text field

Sutro Biopharma is a clinical-stage biopharmaceutical company that has developed a proprietary integrated cell-free protein synthesis platform (XpressCF™ and XpressCF+™) to create a broad variety of optimally designed, next-generation protein therapeutics for cancer. The company's product portfolio includes wholly owned ADC programs: STRO-004 (tissue factor-targeting TOP1i ADC in Phase 1), STRO-006, and STRO-227. Sutro also licenses its XpressCF technology to partners including Vaxcyte for vaccine development and has partnered with Astellas Pharma on dual-payload immunostimulatory ADC programs including ASP2998. The company focuses on antibody-drug conjugates for solid tumors and leverages its platform for cytokine-based immuno-oncology therapeutics, ADCs, and bispecific antibodies.

Product and service7 records
1XpressCF Platform
CategoryPlatform Technology
Description

Proprietary cell-free protein synthesis technology that enables rapid, parallel production of protein structures, supports incorporation of non-natural amino acids, and accelerates drug discovery and development for antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine-based therapeutics. The platform is offered to pharmaceutical partners through licensing and collaboration agreements.

2XpressCF+ Platform
CategoryPlatform Technology
Description

Enhanced cell-free protein synthesis platform incorporating one or more non-natural amino acids for site-specific conjugation, enabling homogeneous antibody-drug conjugate design and optimized therapeutic candidates. The platform is licensed to partners for use in therapeutic development.

3STRO-004
CategoryClinical Pipeline Product
Description

Next-generation tissue factor-targeting exatecan antibody-drug conjugate with a drug-to-antibody ratio of 8, in Phase 1 clinical trial for tissue factor-expressing solid tumors. Initial clinical data are expected mid-2026.

4STRO-006
CategoryClinical Pipeline Product
Description

Next-generation antibody-drug conjugate candidate targeting PTK7, with IND submission planned for 2026.

5STRO-227
CategoryClinical Pipeline Product
Description

Antibody-drug conjugate candidate with IND submission targeted for late 2026.

6XpressCF Cell-Free Protein Synthesis (Licensed to Vaxcyte)
CategoryLicensed Technology
Description

Cell-free protein synthesis technology licensed exclusively to Vaxcyte for use in developing pneumococcal conjugate vaccine candidates, including VAX-31 (which received FDA Breakthrough Therapy designation) and VAX-24.

7ASP2998 (Partnered with Astellas)
CategoryPartnered Product
Description

TROP2-targeted immunostimulatory antibody-drug conjugate developed on Sutro's iADC platform, advanced into clinical trials by Astellas Pharma as a partnered program.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-19
Description

Strategic partnership on dual-payload immunostimulatory ADCs (iADC). Astellas has advanced ASP2998 (TROP2-targeted iADC) into clinical trials, triggering $17.5 million in combined milestone payments. Patient dosing commenced under the partnership in Q2 2026.

Strategic tierCoreTypeTechnology or Integration
Description

Vaxcyte licenses XpressCF cell-free protein synthesis technology exclusively from Sutro for developing pneumococcal conjugate vaccines. Vaxcyte exercises option for XtractCF manufacturing rights totaling $75 million across 2023-2024. Sutro retains equity interest and single digit royalties on net sales.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cytokine derivatives collaboration with rights to develop up to three programs for cancer and autoimmune disorders. Merck paid $60 million upfront plus $20 million in Series E investment and $10 million in common stock at IPO. Sutro eligible for up to $1.6 billion in aggregate milestone payments plus tiered royalties.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on BCMA ADC and up to four bispecific antibodies for immuno-oncology. Sutro received $95 million upfront plus additional payments. Eligible for up to $295-393 million in milestones and tiered royalties on worldwide sales.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

ADC collaboration with rights to designate up to six cancer targets against which Sutro discovers and optimizes up to three ADC product candidates per target. EMD Serono selected all six target antigens. Sutro eligible for up to $52.5 million per product in pre-commercial payments plus tiered royalties.

6Boehringer Ingelheim
Strategic tierCoreTypeTechnology or Integration
Description

CDMO partnership for GMP manufacturing of XpressCF-produced proteins. Boehringer Ingelheim scaled up the platform to 4,500L GMP manufacturing at Vienna facility in January 2025, marking first large-scale commercial validation of cell-free protein synthesis by a third-party CDMO.

marketsandmarkets.com
Strategic tierCoreTypeTechnology or Integration
Description

Exclusive license from Stanford for patent rights covering methods related to in vitro protein synthesis used in XpressCF Platform. Includes 15 U.S. issued patents and 44 ex-U.S. patents. Annual license maintenance fees of $75,000 plus low single digit royalties on net sales.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer, with a similar pipeline-stage profile, platform-based discovery approach, and reliance on partnership revenue. Most directly comparable in terms of size, business model, and clinical focus.

TypeDirect peer
Description

Clinical-stage ADC developer with a similar focus on next-generation antibody-drug conjugates for solid tumors. Comparable in company size, clinical pipeline depth, and dependence on capital markets to fund development.

TypeDirect peer
Description

Clinical-stage company developing immunostimulatory ADCs (ISACs), which is conceptually adjacent to Sutro's dual-payload immunostimulatory ADC (iADC) platform. Similar size, similar platform technology focus, and similar clinical-stage profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing both antibody-drug conjugates and bispecific antibodies for cancer, directly overlapping with Sutro's ADC and bispecific antibody programs. Similar platform-based discovery model and partnership-driven business model.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and ADC candidates with proprietary platforms. Similar company size, similar business model reliant on partnerships and licensing, and overlapping therapeutic focus in oncology.

TypeBroad incumbent
Description

Global pharmaceutical company and ADC market leader with approved products Enhertu and Datroway developed in partnership with AstraZeneca. Represents the dominant competitive threat in the ADC space and is also a potential licensor or acquirer of ADC technologies.

TypeBroad incumbent
Description

Global pharmaceutical company with a major ADC franchise (Enhertu, Datroway) developed in partnership with Daiichi Sankyo. Competes in the same therapeutic areas and could be a potential partner or acquirer for next-generation ADC technologies.

TypeBroad incumbent
Description

Global pharmaceutical company that acquired ImmunoGen in 2024 to gain the Elahere ADC franchise. ImmunoGen was historically a direct peer, and AbbVie now competes in the ADC space with substantially greater resources and commercial infrastructure.

TypeBroad incumbent
Description

Global pharmaceutical company that acquired Seagen for $43B in 2023, gaining a leading ADC portfolio (Adcetris, Padcev, Tukysa, Tivdak). Represents one of the largest commercial-stage ADC competitors with significant resources and pipeline breadth.

TypeEmerging player
Description

Chinese biopharmaceutical company with a growing ADC pipeline and existing approved biologics. Represents an emerging player in the ADC space that is developing competitive products for global markets, particularly in oncology indications overlapping with Sutro's pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sutro Biopharma

Biopharmaceutical Oncology Therapeuticssutrobio.com

Sutro Biopharma is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for oncology using its proprietary XpressCF cell-free protein synthesis platform, monetizing through pharma collaborations while advancing a focused internal ADC pipeline.

What Sutro Biopharma does

Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, that develops next-generation protein therapeutics for cancer using its proprietary cell-free protein synthesis platform, XpressCF. The platform separates cell-mass production from protein production, enabling rapid parallel evaluation of thousands of protein variants in under 24 hours, efficient site-specific incorporation of non-natural amino acids, and generation of homogeneous single-species antibody-drug conjugates (ADCs) rather than heterogeneous mixtures. Sutro's wholly-owned pipeline comprises tissue factor-targeting exatecan ADC STRO-004 (Phase 1, dosed December 2025), PTK7-targeting STRO-006 (IND planned 2026), and STRO-227 (IND planned late 2026). The company is also advancing immunostimulatory dual-payload ADCs (iADCs) in collaboration with Astellas, with ASP2998 (TROP2-targeted iADC) entering clinical trials in Q2 2026.

Sutro monetizes primarily through strategic collaborations and licensing rather than direct commercialization. Core partnerships include Merck (cytokine derivatives, up to $1.6 billion in potential milestones), Celgene/BMS (BCMA ADC and bispecifics), EMD Serono (up to six ADC targets), Astellas (dual-payload iADCs), and Vaxcyte (exclusive license of XpressCF for pneumococcal conjugate vaccines VAX-31 and VAX-24). A June 2023 royalty financing with Blackstone Life Sciences provided $140 million upfront (with up to $250 million in milestones) in exchange for a 4% royalty interest in Vaxcyte's future product sales. FY2025 collaboration revenue of $102.5 million (65% growth from $62.0 million in 2024) was driven by Astellas and Ipsen milestones, with cumulative collaboration payments reaching approximately $1.016 billion through December 2025.

Following a March 2025 strategic review, Sutro deprioritized luveltamab tazevibulin (STRO-002), reduced its workforce by approximately one third in October 2025, and narrowed focus to three ADC programs. The company operates cGMP manufacturing at a San Carlos facility and benefits from a January 2025 scale-up of XpressCF to 4,500L GMP at Boehringer Ingelheim's Vienna site — the first large-scale third-party CDMO validation of cell-free protein synthesis. As of early 2026, Sutro had a market capitalization of approximately $406 million, ~97% institutional ownership, and a cash position of $141.4 million extended to Q2 2028 following a February 2026 $110 million public offering.

Sutro Biopharma firmographics

Firmographics
Name
Sutro Biopharma
Legal name
Sutro Biopharma, Inc.
Website
https://sutrobio.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Sutro Biopharma is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for oncology using its proprietary XpressCF cell-free protein synthesis platform, monetizing through pharma collaborations while advancing a focused internal ADC pipeline.
Ownership category
akta.pro rank

Sutro Biopharma industry classification

Industry
Product category
Biopharmaceutical Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cell-free protein synthesis
  • Antibody-drug conjugates
  • Oncology therapeutics development
  • Biologics manufacturing platform
  • Clinical-stage biopharmaceuticals

Where Sutro Biopharma is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Sutro Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Collaboration and Partnership Revenue: Revenue from upfront payments, research and development funding, milestone payments, and royalty payments from strategic partnerships with pharmaceutical companies including Merck, Celgene, EMD Serono, and Astellas. FY2025 revenue was $102.5 million, a 65% increase from $62.0 million in 2024, driven by collaboration milestones from Astellas and Ipsen.
  2. Royalty Income from Vaxcyte: Blackstone provides $140 million upfront to Sutro in exchange for 4% royalty interest on future sales of Vaxcyte's products, including pneumococcal conjugate vaccine VAX-24. Sutro retains equity interest in Vaxcyte.
  3. Equity Financing: Underwritten public offerings of common stock to institutional investors. February 2026 offering raised approximately $110 million through sale of 7,868,383 shares at $13.98 per share.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels9 records

Sutro Biopharma product offering

Product offering

Core offering

Sutro Biopharma develops next-generation protein therapeutics for cancer using its proprietary XpressCF and XpressCF+ cell-free protein synthesis platforms. The company creates antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine-based therapeutics through site-specific incorporation of non-natural amino acids, producing homogeneous single-species conjugates. Its clinical pipeline includes STRO-004 (tissue factor ADC in Phase 1), STRO-006, and STRO-227, alongside partnered programs with Astellas (ASP2998 iADC) and Vaxcyte (pneumococcal conjugate vaccines).

Product overview

Sutro Biopharma is a clinical-stage biopharmaceutical company that has developed a proprietary integrated cell-free protein synthesis platform (XpressCF™ and XpressCF+™) to create a broad variety of optimally designed, next-generation protein therapeutics for cancer. The company's product portfolio includes wholly owned ADC programs: STRO-004 (tissue factor-targeting TOP1i ADC in Phase 1), STRO-006, and STRO-227. Sutro also licenses its XpressCF technology to partners including Vaxcyte for vaccine development and has partnered with Astellas Pharma on dual-payload immunostimulatory ADC programs including ASP2998. The company focuses on antibody-drug conjugates for solid tumors and leverages its platform for cytokine-based immuno-oncology therapeutics, ADCs, and bispecific antibodies.

Differentiator

Problem solved

Functional benefit

Products and services

  • XpressCF Platform Proprietary cell-free protein synthesis technology that enables rapid, parallel production of protein structures, supports incorporation of non-natural amino acids, and accelerates drug discovery and development for antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine-based therapeutics. The platform is offered to pharmaceutical partners through licensing and collaboration agreements.
  • XpressCF+ Platform Enhanced cell-free protein synthesis platform incorporating one or more non-natural amino acids for site-specific conjugation, enabling homogeneous antibody-drug conjugate design and optimized therapeutic candidates. The platform is licensed to partners for use in therapeutic development.
  • STRO-004 Next-generation tissue factor-targeting exatecan antibody-drug conjugate with a drug-to-antibody ratio of 8, in Phase 1 clinical trial for tissue factor-expressing solid tumors. Initial clinical data are expected mid-2026.
  • STRO-006 Next-generation antibody-drug conjugate candidate targeting PTK7, with IND submission planned for 2026.
  • STRO-227 Antibody-drug conjugate candidate with IND submission targeted for late 2026.
  • XpressCF Cell-Free Protein Synthesis (Licensed to Vaxcyte) Cell-free protein synthesis technology licensed exclusively to Vaxcyte for use in developing pneumococcal conjugate vaccine candidates, including VAX-31 (which received FDA Breakthrough Therapy designation) and VAX-24.
  • ASP2998 (Partnered with Astellas) TROP2-targeted immunostimulatory antibody-drug conjugate developed on Sutro's iADC platform, advanced into clinical trials by Astellas Pharma as a partnered program.

Quantifiable outcome

  • 65% revenue growth in FY2025 to $102.5 million
  • +1 more outcomes

Companies that use Sutro Biopharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Sutro Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Sutro Biopharma partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Astellas PharmacoreStrategic or Co-development Partner · 19 April 2026Strategic partnership on dual-payload immunostimulatory ADCs (iADC). Astellas has advanced ASP2998 (TROP2-targeted iADC) into clinical trials, triggering $17.5 million in combined milestone payments. Patient dosing commenced under the partnership in Q2 2026.
  • VaxcytecoreTechnology or IntegrationVaxcyte licenses XpressCF cell-free protein synthesis technology exclusively from Sutro for developing pneumococcal conjugate vaccines. Vaxcyte exercises option for XtractCF manufacturing rights totaling $75 million across 2023-2024. Sutro retains equity interest and single digit royalties on net sales.
  • Merck (Merck Sharp & Dohme)coreStrategic or Co-development PartnerCytokine derivatives collaboration with rights to develop up to three programs for cancer and autoimmune disorders. Merck paid $60 million upfront plus $20 million in Series E investment and $10 million in common stock at IPO. Sutro eligible for up to $1.6 billion in aggregate milestone payments plus tiered royalties.
  • Celgene (Bristol-Myers Squibb)coreStrategic or Co-development PartnerCollaboration on BCMA ADC and up to four bispecific antibodies for immuno-oncology. Sutro received $95 million upfront plus additional payments. Eligible for up to $295-393 million in milestones and tiered royalties on worldwide sales.
  • EMD Serono (Merck KGaA)minorStrategic or Co-development PartnerADC collaboration with rights to designate up to six cancer targets against which Sutro discovers and optimizes up to three ADC product candidates per target. EMD Serono selected all six target antigens. Sutro eligible for up to $52.5 million per product in pre-commercial payments plus tiered royalties.
  • Boehringer IngelheimcoreTechnology or IntegrationCDMO partnership for GMP manufacturing of XpressCF-produced proteins. Boehringer Ingelheim scaled up the platform to 4,500L GMP manufacturing at Vienna facility in January 2025, marking first large-scale commercial validation of cell-free protein synthesis by a third-party CDMO.
  • Stanford UniversitycoreTechnology or IntegrationExclusive license from Stanford for patent rights covering methods related to in vitro protein synthesis used in XpressCF Platform. Includes 15 U.S. issued patents and 44 ex-U.S. patents. Annual license maintenance fees of $75,000 plus low single digit royalties on net sales.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Sutro Biopharma competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer, with a similar pipeline-stage profile, platform-based discovery approach, and reliance on partnership revenue. Most directly comparable in terms of size, business model, and clinical focus.
  • Pyxis Oncology: Clinical-stage ADC developer with a similar focus on next-generation antibody-drug conjugates for solid tumors. Comparable in company size, clinical pipeline depth, and dependence on capital markets to fund development.
  • Bolt Biotherapeutics: Clinical-stage company developing immunostimulatory ADCs (ISACs), which is conceptually adjacent to Sutro's dual-payload immunostimulatory ADC (iADC) platform. Similar size, similar platform technology focus, and similar clinical-stage profile.
  • MacroGenics: Clinical-stage biopharmaceutical company developing both antibody-drug conjugates and bispecific antibodies for cancer, directly overlapping with Sutro's ADC and bispecific antibody programs. Similar platform-based discovery model and partnership-driven business model.
  • Zymeworks: Clinical-stage biotech developing bispecific antibodies and ADC candidates with proprietary platforms. Similar company size, similar business model reliant on partnerships and licensing, and overlapping therapeutic focus in oncology.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical company and ADC market leader with approved products Enhertu and Datroway developed in partnership with AstraZeneca. Represents the dominant competitive threat in the ADC space and is also a potential licensor or acquirer of ADC technologies.
  • AstraZeneca: Global pharmaceutical company with a major ADC franchise (Enhertu, Datroway) developed in partnership with Daiichi Sankyo. Competes in the same therapeutic areas and could be a potential partner or acquirer for next-generation ADC technologies.
  • AbbVie (acquired ImmunoGen): Global pharmaceutical company that acquired ImmunoGen in 2024 to gain the Elahere ADC franchise. ImmunoGen was historically a direct peer, and AbbVie now competes in the ADC space with substantially greater resources and commercial infrastructure.
  • Pfizer (acquired Seagen): Global pharmaceutical company that acquired Seagen for $43B in 2023, gaining a leading ADC portfolio (Adcetris, Padcev, Tukysa, Tivdak). Represents one of the largest commercial-stage ADC competitors with significant resources and pipeline breadth.

Emerging players

  • Innovent Biologics: Chinese biopharmaceutical company with a growing ADC pipeline and existing approved biologics. Represents an emerging player in the ADC space that is developing competitive products for global markets, particularly in oncology indications overlapping with Sutro's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Sutro Biopharma social profiles

Digital presence

Sutro Biopharma compliance and trust

Trust signal

Compliance1 record

Sutro Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sutro Biopharma leadership team

Management profile

Number of profiles

Profiles16 records

Sutro Biopharma funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sutro Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sutro Biopharma

What does Sutro Biopharma do?

Sutro Biopharma develops next-generation protein therapeutics for cancer using its proprietary XpressCF and XpressCF+ cell-free protein synthesis platforms. The company creates antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine-based therapeutics through site-specific incorporation of non-natural amino acids, producing homogeneous single-species conjugates. Its clinical pipeline includes STRO-004 (tissue factor ADC in Phase 1), STRO-006, and STRO-227, alongside partnered programs with Astellas (ASP2998 iADC) and Vaxcyte (pneumococcal conjugate vaccines).

Is Sutro Biopharma a public or private company?

Sutro Biopharma is a public company. It is classified as public and is currently operating.

When was Sutro Biopharma founded?

Sutro Biopharma was founded in 2018. It employs 101 to 250 people.

Where is Sutro Biopharma based?

Sutro Biopharma is headquartered in South San Francisco, United States, in the North America region.

How does Sutro Biopharma make money?

Three revenue lines are on record. Collaboration and Partnership Revenue is the primary driver. The others are royalty Income from Vaxcyte and equity Financing.

Who are Sutro Biopharma's main competitors?

Direct peers on record are Mersana Therapeutics, Pyxis Oncology, Bolt Biotherapeutics, MacroGenics and Zymeworks. Broad incumbents are Daiichi Sankyo, AstraZeneca, AbbVie (acquired ImmunoGen) and Pfizer (acquired Seagen). Innovent Biologics is listed as an emerging player.

Does Sutro Biopharma have an API?

No public API is recorded for Sutro Biopharma.

What industry is Sutro Biopharma in?

Sutro Biopharma's product category is Biopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBarclays maintains Sutro Biopharma at Overweight, raises price target to $57 from $56Barclays maintained Sutro Biopharma at Overweight and raised its price target to $57 from $56. The target implies an upside of 494.4% from the Nov 12 close of $9.59.The future of tradingSutro Biopharma Inc reports results for the quarter ended September 30 - Earnings SummarySutro Biopharma reported a quarterly adjusted loss of $1.90 per share for the quarter ended September 30, beating the mean analyst estimate of -$1.91. Revenue fell 6.1% to $9.10 million, missing the expected $10.34 million. The company's shares had fallen 36.3% this quarter.Quiver QuantitativeSutro Biopharma Reports $9.1 Million Third-Quarter Revenue | STRO Stock NewsSutro Biopharma reported third-quarter 2026 revenue of $9.1 million and a net loss of $31.5 million, down from $9.7 million revenue and $56.9 million loss a year earlier. The company held $142.2 million in cash and expects its operating plan to support operations into the first half of 2028.FierceBiotechMerck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’Merck abandoned its IL-2 agonist MK-1484, a Sutro Biopharma-partnered candidate for solid tumors, citing routine pipeline prioritization. The program, tested in 2022, was scrapped without further details. Merck no longer lists any IL-2 assets in its pipeline.Tipranks3 ‘Strong Buy’ High-Risk Stocks That Could Offer Mouthwatering ReturnsAnalysts rate Sutro Biopharma, Backblaze, and Ultra Clean Holdings as Strong Buy, projecting at least 170% upside. Sutro leads with 443% upside, Backblaze 192%, and Ultra Clean 172%. The stocks are in volatile industries, offering high risk but potential for big returns.MarketBeatSutro Biopharma (NASDAQ:STRO) Raised to "Sell" at Wall Street ZenWall Street Zen upgraded Sutro Biopharma from a strong sell to a sell rating. The company reported a loss of $2.33 per share, missing estimates, and analysts have a consensus Buy rating with a $49.50 price target.MarketBeatSutro Biopharma (STRO) Expected to Post Earnings on ThursdaySutro Biopharma is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $1.66 per share and revenue of $13.61 million. The company's stock opened at $9.29, and analysts have an average rating of Buy with a target price of $49.50.MarketBeatSutro Biopharma, Inc. (NASDAQ:STRO) Stock Rated "Buy" by Wall Street BrokeragesWall Street analysts rate Sutro Biopharma a Buy, with 12 of 13 firms covering the stock. The average 12-month price target is $49.50, and the company reported Q2 EPS of -$2.33, missing the -$2.19 consensus. Analysts project a current-year EPS of -$8.41.Markets DailyProtagonist Therapeutics (NASDAQ:PTGX) & Sutro Biopharma (NASDAQ:STRO) Financial ReviewProtagonist Therapeutics and Sutro Biopharma are compared on financial metrics, with Protagonist showing higher profitability and institutional ownership. Sutro Biopharma has a lower P/E ratio and a higher analyst upside target of 339.61% versus Protagonist's 14.87%.Investing.comH.C. Wainwright reiterates Sutro Biopharma stock rating at buyH.C. Wainwright reiterated a Buy rating on Sutro Biopharma, keeping its $50 price target despite the stock's recent decline. The firm reviewed World ADC conference presentations, noting preclinical data and five investor questions. Analysts' targets range from $10 to $61, with Stifel initiating a Buy at $48.